UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

☒     QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended: September 30, 2026

 

☐     TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from __________ to __________

 

Commission File Number: 000-23476

 

GROOVE BOTANICALS, INC.

(Exact name of registrant as specified in its charter)

 

Nevada

 

84-1168832

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

 

 

310 Fourth Avenue South, Suite 7000

Minneapolis, MN

 

55415

(Address of principal executive offices)

 

(Zip Code)

 

(612)-315-5068

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act: None

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

None

 

N/A

 

N/A

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒     No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒     No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. 

 

Large accelerated filer 

☐

Accelerated filer 

☐

Non-accelerated Filer

☒

Smaller reporting company 

☒

 

 

Emerging growth company 

☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐     No ☒

 

As of November 12, 2026 there were 59,643,062 shares of the registrant’s common stock outstanding.

 

 

  

GROOVE BOTANICALS, INC.

TABLE OF CONTENTS

 

 

 

 

Page

 

 

PART I – FINANCIAL INFORMATION

 

 

 

 

 

 

 

 

 

 

Item 1.

Financial Statements (Unaudited)

 

 

3

 

 

 

 

 

 

 

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

 

14

 

 

 

 

 

 

 

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

 

 

19

 

 

 

 

 

 

 

Item 4.

Controls and Procedures

 

 

19

 

 

 

 

 

 

 

 

PART II – OTHER INFORMATION

 

 

 

 

 

 

 

 

 

 

Item 1.

Legal Proceedings

 

 

21

 

 

 

 

 

 

 

Item 1A.

Risk Factors

 

 

21

 

 

 

 

 

 

 

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

 

 

21

 

 

 

 

 

 

 

Item 3.

Defaults Upon Senior Securities

 

 

21

 

 

 

 

 

 

 

Item 4.

Mine Safety Disclosures

 

 

21

 

 

 

 

 

 

 

Item 5.

Other Information

 

 

21

 

 

 

 

 

 

 

Item 6.

Exhibits

 

 

22

 

 

 

 

 

 

 

 

SIGNATURES

 

 

23

 

 

 
2

Table of Contents

 

PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

 

Groove Botanicals, Inc.

Condensed Consolidated Balance Sheets

Unaudited

 

 

 

September 30,

2026

 

 

March 31,

2026

 

ASSETS

 

 

 

 

 

 

Current Assets:

 

 

 

 

 

 

Cash

 

$1,866

 

 

$1,502

 

Other receivable

 

 

196

 

 

 

-

 

Prepaid Expenses

 

 

16,700

 

 

 

2,930

 

Total Current Assets

 

 

18,762

 

 

 

4,432

 

TOTAL ASSETS

 

$18,762

 

 

$4,432

 

 

 

 

 

 

 

 

 

 

LIABILITIES & STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

 

 

Current Liabilities:

 

 

 

 

 

 

 

 

Accounts Payable and Accrued Liabilities

 

$63,678

 

 

$69,309

 

Advances Payable

 

 

12,500

 

 

 

-

 

Related Party Payable

 

 

796,155

 

 

 

747,961

 

Dividends payable

 

 

624,645

 

 

 

435,825

 

Dividends payable, related party

 

 

140,000

 

 

 

219,585

 

Total Current Liabilities

 

 

1,636,978

 

 

 

1,472,680

 

Total Liabilities

 

 

1,636,978

 

 

 

1,472,680

 

 

 

 

 

 

 

 

 

 

Stockholders’ Equity

 

 

 

 

 

 

 

 

Preferred Stock, Series A, $0.10 par value, 100 shares authorized; 100 shares issued and outstanding as of September 30, 2026, and March 31, 2026

 

 

10

 

 

 

10

 

Preferred Stock, Series B, $0.10 par value, 2,000 shares authorized; 1,983 shares issued and outstanding as of September 30, 2026, and March 31, 2026

 

 

198

 

 

 

198

 

Common Stock, $0.001 par value, 200,000,000 shares authorized. and 59,643,062 shares issued and outstanding as of September 30, 2026, and March 31, 2026

 

 

59,643

 

 

 

59,643

 

Additional paid-in capital

 

 

34,038,869

 

 

 

34,026,869

 

Accumulated deficit

 

 

(35,716,936 )

 

 

(35,554,968 )

Total stockholders’ deficit

 

 

(1,618,216 )

 

 

(1,468,248 )

TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT

 

$18,762

 

 

$4,432

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

 
3

Table of Contents

 

Groove Botanicals, Inc.

Unaudited Condensed Consolidated Statements of Operations

 

 

 

For the Three Months Ended

September 30,

 

 

For the Six Months Ended

September 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Selling, General and Administrative Expenses

 

$8,092

 

 

$18,018

 

 

$26,811

 

 

$36,983

 

Rent

 

 

3,600

 

 

 

3,600

 

 

 

7,200

 

 

 

7,200

 

Legal and Professional Expenses

 

 

21,070

 

 

 

10,765

 

 

 

27,069

 

 

 

26,370

 

Total operating expenses

 

 

32,762

 

 

 

32,383

 

 

 

61,080

 

 

 

70,553

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating loss

 

 

(32,762 )

 

 

(32,383 )

 

 

(61,080 )

 

 

(70,553 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other income (expense)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other income

 

$1,200

 

 

 

-

 

 

$8,347

 

 

 

-

 

Total other income

 

$1,200

 

 

 

-

 

 

$8,347

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net (loss)

 

$(31,562 )

 

$(32,383 )

 

$(52,733 )

 

$(70,553 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Dividend on Preferred Stock

 

 

(54,617 )

 

 

(54,618 )

 

 

(109,235 )

 

 

(109,235 )

Net (loss) attributable to common shareholders

 

$(86,179 )

 

$(87,001 )

 

$(161,968 )

 

$(179,788 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted loss per common share

 

$(0.00 )

 

$(0.00 )

 

$(0.00 )

 

$(0.00 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average common shares outstanding – Basic and diluted

 

 

59,643,062

 

 

 

59,643,062

 

 

 

59,643,062

 

 

 

59,643,062

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

 
4

Table of Contents

 

Groove Botanicals, Inc.

Unaudited Condensed Consolidated Statements of Stockholders’ Equity

For the Three and Six Months Ended September 30, 2026, and 2025

 

 

 

Series A

Preferred Stock

 

 

Series B

Preferred Stock

 

 

Common Stock

 

 

Additional

Paid In

Capital

 

 

Accumulated Deficit

 

 

Total

 

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

Amount

 

 

Amount

 

 

Amount

 

Balance, March 31, 2025

 

 

100

 

 

 

10

 

 

 

1,983

 

 

 

198

 

 

 

59,643,062

 

 

 

59,643

 

 

 

34,026,869

 

 

 

(35,196,581 )

 

 

(1,109,861 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accrued dividend

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(54,617 )

 

 

(54,617 )

Net (loss)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(38,170 )

 

 

(38,170 )

Balance, June 30, 2025

 

 

100

 

 

$10

 

 

 

1,983

 

 

$198

 

 

 

59,643,062

 

 

$59,643

 

 

$34,026,869

 

 

$(35,289,368 )

 

$(1,202,648 )

Accrued dividend

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(54,618 )

 

 

(54,618 )

Net (loss)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(32,383 )

 

 

(32,383 )

Balance, September 30, 2025

 

 

100

 

 

$10

 

 

 

1,983

 

 

$198

 

 

 

59,643,062

 

 

$59,643

 

 

$34,026,869

 

 

$(35,376,369 )

 

$(1,289,649 )

 

 

 

Series A

Preferred Stock

 

 

Series B

Preferred Stock

 

 

Common Stock

 

 

Additional Paid In

Capital

 

 

Accumulated Deficit

 

 

Total

 

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

Amount

 

 

Amount

 

 

Amount

 

Balance, March 31, 2026

 

 

100

 

 

 

10

 

 

 

1,983

 

 

 

198

 

 

 

59,643,062

 

 

 

59,643

 

 

 

34,026,869

 

 

 

(35,554,968 )

 

 

(1,468,248 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accrued dividend

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(54,618 )

 

 

(54,618 )

Net (loss)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(21,171 )

 

 

(21,171 )

Balance, June 30, 2026

 

 

100

 

 

$10

 

 

 

1,983

 

 

$198

 

 

 

59,643,062

 

 

$59,643

 

 

$34,026,869

 

 

$(35,630,757 )

 

$(1,544,037 )

Forgiveness of related party compensation

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

12,000

 

 

 

-

 

 

 

12,000

 

Accrued dividend

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(54,617 )

 

 

(54,617 )

Net (loss)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(31,562 )

 

 

(31,562 )

Balance, September 30, 2026

 

 

100

 

 

$10

 

 

 

1,983

 

 

$198

 

 

 

59,643,062

 

 

$59,643

 

 

$34,038,869

 

 

$(35,716,936 )

 

$(1,618,216 )

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

 
5

Table of Contents

 

Groove Botanicals, Inc.

Unaudited Condensed Consolidated Statements of Cash Flows

 

 

 

For the Six Months Ended

September 30,

 

 

 

2026

 

 

2025

 

Cash Flow From Operating Activities

 

 

 

 

 

 

Net Loss

 

$(52,733 )

 

$(70,553 )

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

Increase in accrued related-party compensation

 

 

12,000

 

 

 

24,000

 

Costs paid directly by related party on behalf of the Company

 

 

9,694

 

 

 

10,820

 

Changes in working capital

 

 

 

 

 

 

 

 

Decrease (Increase) in Other Receivable

 

 

(196 )

 

 

—

 

Decrease (Increase) in Prepaid Expenses

 

 

(13,770 )

 

 

(4,194 )

Increase (Decrease) in Accounts Payable and Accrued Liabilities

 

 

(5,631 )

 

 

(4,927 )

Net Cash Used in Operating Activities

 

 

(50,636 )

 

 

(44,854 )

 

 

 

 

 

 

 

 

 

Cash Flow From Investing Activities

 

 

—

 

 

 

—

 

Net Cash From Investing Activities

 

 

—

 

 

 

—

 

 

 

 

 

 

 

 

 

 

Cash Flow From Financing Activities

 

 

 

 

 

 

 

 

Advances from related party

 

 

38,500

 

 

 

46,500

 

Repayments to related party

 

 

—

 

 

 

(2,196 )

Proceeds from advances payable

 

 

12,500

 

 

 

—

 

Net Cash From Financing Activities

 

 

51,000

 

 

 

44,304

 

 

 

 

 

 

 

 

 

 

Net Change in Cash

 

 

364

 

 

 

(550 )

 

 

 

 

 

 

 

 

 

Cash at Beginning of Period

 

 

1,502

 

 

 

2,042

 

 

 

 

 

 

 

 

 

 

Cash at End of Period

 

$1,866

 

 

$1,492

 

 

 

 

 

 

 

 

 

 

Net cash paid for:

 

 

 

 

 

 

 

 

Interest

 

$—

 

 

$—

 

Income Taxes

 

$—

 

 

$—

 

 

 

 

 

 

 

 

 

 

Non-cash investing and financing activities:

 

 

 

 

 

 

 

 

Dividends accrued on preferred stock

 

$109,235

 

 

$109,235

 

Forgiveness of related party compensation credited to additional paid-in capital

 

$12,000

 

 

$—

 

Reclassification of Series B dividends payable from related party

 

$107,884

 

 

$—

 

Costs paid directly by related party on behalf of the Company

 

$9,694

 

 

$10,820

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

 
6

Table of Contents

 

GROOVE BOTANICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE AND SIX MONTHS ENDED SEPTEMBER 30, 2026 AND 2025

(Unaudited)

 

NOTE 1 – ORGANIZATION AND OPERATIONS

 

Current Operations

 

Groove Botanicals, Inc. (the “Company”), (formerly known as Avalon Oil & Gas, Inc.), was originally incorporated in Colorado on April 25, 1991, under the name Snow Runner (USA), Inc. The Company was the general partner of Snow Runner (USA) Ltd.; a Colorado limited partnership to sell proprietary snow skates under the name “Sled Dogs” which was dissolved in August 1992. In late 1993, the Company relocated its operations to Minnesota and in January 1994 changed our name to Snow Runner, Inc. In November 1994 we changed our name to the Sled Dogs Company. On May 25, 1999, we filed articles of merger with Xdogs.com Inc., changing our state of domicile to Nevada. On June 22, 2005, the Corporation changed our name from XDOGS.com, Inc. to Avalon Oil and Gas, Inc. On May 14, 2018, the Corporation changed our name from Avalon Oil and Gas, Inc., to Groove Botanicals, Inc. Until August 2, 2021, when we filed a 15-12B to suspend duty to file reports under sections 13 and 15(d) of the securities exchange act of 1934, we were a reporting company. Subsequently, on September 14, 2023, we filed a Form 10 with the Securities and Exchange Commission, which became effective 60 days later.

 

Since inception we have operated unsuccessfully, in various different industries. In September 2026, the Company engaged legal counsel in connection with a planned corporate reorganization, including the preparation of an information statement on Schedule 14C related to an amendment to the Company’s Series A Preferred Stock and the authorization of Series C Preferred Stock. The Company paid counsel a $10,000 retainer using an advance from an unrelated third party (Note 6). The Company filed the preliminary information statement with the SEC on October 20, 2026. In November 2026, the Company engaged the same legal counsel for intellectual property and licensing matters. The Company also intends to change our name from Groove Botanicals, Inc., to Nordmark Technologies, Inc., to better describe our corporate focus and as such has reserved the name with the State of Nevada. The name change will require approval of a majority of our stockholders and by the Financial Industry Regulatory Authority (“FINRA”). There can be no assurance that the name change will be completed.

 

The Company is an early-stage company. We intend to identify and evaluate early-stage intellectual property and applied technologies that may originate from, or be developed within, the research ecosystems of Norwegian universities, university hospitals, applied research institutions, and related technology-transfer or innovation organizations, and to assess whether selected technologies may be suitable for licensing, further development, or commercialization in North America through licensing, strategic relationships, commercial partnerships, customer arrangements, or other commercial structures, if available.

 

We have selected an initial geographic focus on Norway as we believe a concentrated review of a defined research ecosystem may allow us to evaluate opportunities more efficiently. We believe certain Norwegian institutions are active in selected applied-technology sectors that may be relevant to North American markets, which may include energy and offshore technology, maritime and ocean industries, aquaculture, carbon capture, health sciences, medical technology, and other applied industrial and digital technologies.

 

We are negotiating a Framework Agreement with Ard Innovation AS (“ARD”). ARD is a technology transfer office (TTO) based in Ås, Norway, that is 100% owned by the Norwegian Institute of Bioeconomy Research (NIBIO) and the Norwegian University of Life Sciences (NMBU), to establish a structured framework for cooperation and dialogue between the Company and ARD with a view to the commercialization of their technologies and conclude Project Agreements to commercialize these technologies for North American markets. We are also negotiating a Framework Agreement with Inven2. Inven2 is headquartered in Oslo, Norway and is the largest technology transfer office in Norway. It is owned by the University of Oslo and the South-Eastern Norway Regional Health Authority (including Oslo University Hospital). Inven2 turns academic and clinical research into commercial products, services, and startup companies that benefit society, focusing heavily on life sciences, healthcare, Greentech, and IT. We have not entered into any formal licensing agreements or formal arrangements with any of these institutions or any other Norwegian research organization except as described above and have not identified any specific technology or intellectual property rights under contract, and do not have proprietary or exclusive access to any technology pipeline.

 

We are in an early stage of development, we have not entered into any formal licensing agreements or formal arrangements with any university, research institution, or technology transfer organization to date, and there can be no assurance that suitable technologies will be identified, licensed, developed, or successfully commercialized.

 

 
7

Table of Contents

 

Once the Series C Preferred Stock are designated and available for issuance the Company intends to complete a financing using the Series C Preferred Stock to raise up to $15,000,000 for operations, including acquiring technologies that management intends to identify. The Company has no commitments from any investor to purchase Series C Preferred Stock, and there can be no assurance that any Series C Preferred Stock will be sold. The Series C Preferred Stock has not been, and is not expected to be, registered under the Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from registration. This disclosure does not constitute an offer to sell, or the solicitation of an offer to buy, the Series C Preferred Stock or any other security.

  

As of the date of this filing, Mr. Kent Rodriguez is the Company’s sole officer and director. The Company intends to appoint other directors and officers to the Board with experience in acquisitions and financing.

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”), including the instructions to Form 10-Q and Regulation S-X. Certain information and note disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”), have been condensed or omitted from these statements pursuant to such rules and regulations and, accordingly, they do not include all the information and notes necessary for comprehensive financial statements and should be read in conjunction with our audited financial statements included in our Annual Report on Form 10-K for the year ended March 31, 2026.

 

In the opinion of the management of the Company, all adjustments, which are of a normal recurring nature, necessary for a fair statement of the results for the three and six-month periods have been made. Results for the interim periods presented are not necessarily indicative of the results that might be expected for the entire fiscal year.

 

Basis of Consolidation

 

The Company’s condensed consolidated financial statements include the accounts of Groove Botanicals, Inc., and its two 100% controlled non-operating subsidiaries formed in Wyoming, Biotrex, Inc., and Maxidyne, Inc. Intercompany accounts and transactions have been eliminated in consolidation.

 

Use of Estimates

 

The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Specifically, such estimates were made by the Company for the accrual of Series A and Series B preferred dividends, accrued related-party compensation and advances, and the assessment of the Company’s ability to continue as a going concern. Actual results could differ from those estimates.

 

Reclassifications

 

Certain amounts in prior periods have been reclassified to conform to the current-period presentation. Consulting expenses previously presented separately are included in Selling, General and Administrative Expenses. Company costs paid directly by a related party, previously presented within advances from related party in financing activities, are presented as a non-cash adjustment in operating activities and disclosed as a non-cash financing activity. Any such reclassifications have no effect on previously reported net loss, total stockholders’ equity, or accumulated deficit.

 

Financial Instruments

 

The Company’s financial instruments primarily consist of cash and cash equivalents, other receivables, accounts payable and accrued liabilities, advances payable, related party payable and dividends payable. The carrying values of the Company’s financial instruments approximate fair value. FASB ASC 820, Fair Value Measurements and Disclosures (“ASC 820”) establishes a framework for all fair value measurements and expands disclosures related to fair value measurement and developments. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC 820 requires that assets and liabilities measured at fair value are classified and disclosed in one of the following three categories: Level 1—Quoted market prices for identical assets or liabilities in active markets or observable inputs; Level 2—Significant other observable inputs that can be corroborated by observable market data; and Level 3—Significant unobservable inputs that cannot be corroborated by observable market data. The Company believes that the carrying amounts of cash and cash equivalents, other receivables, accounts payable, advances payable, related party payables and accrued dividends approximate fair value based on either their short-term nature or on terms currently available to the Company in financial markets.

 

 
8

Table of Contents

 

 

Net Loss Per Share

 

The Company computes net income (loss) per share in accordance with ASC 260, Earning per Share. ASC 260 requires presentation of both basic and diluted earnings per share (EPS) on the face of the income statement. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing Diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive. As the Company has continued to report operating losses for the periods covered by this report, the impact of potentially dilutive securities would be anti-dilutive and therefore is not presented.

 

Income Taxes

 

The Company is taxed as a C corporation for income tax purposes. The Company accounts for income taxes under the liability method, and deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying values of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided on deferred tax assets if it is determined that it is more likely than not that the deferred tax asset will not be realized. The Company records interest, net of any applicable related income tax benefit, on potential income tax contingencies as a component of income tax expense. The Company records tax positions taken or expected to be taken in a tax return based upon the amount that is more likely than not to be realized or paid, including in connection with the resolution of any related appeals or other legal processes. Accordingly, the Company recognizes liabilities for certain unrecognized tax benefits based on the amounts that are more likely than not to be settled with the relevant taxing authority. The Company recognizes interest and/or penalties related to unrecognized tax benefits as a component of income tax expense.

 

Recent Accounting Standard Adopted:

 

In November 2023, the FASB issued Accounting Standards Update (“ASU”) 2023-07 – Improvements to Reportable Segment Disclosures, which enhances the disclosures required for reportable segments in annual and interim financial statements, including additional, more detailed information about a reportable segment’s expenses. The standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company adopted ASU 2023-07 for the year ended March 31, 2025, retrospectively to all periods presented in the financial statements. The adoption of this ASU had no impact on reportable segments identified and had no effect on the Company’s financial position, results of operations, or cash flows.

 

In December 2023, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) 2023-09 – Improvements to Income Tax Disclosures, which enhances the transparency and decision usefulness of income tax disclosures. The standard is effective for public companies for annual periods beginning after December 15, 2024. Early adoption is available. The Company adopted ASU 2023-09 for the year beginning April 1, 2025. The adoption of this ASU had no impact on the Company’s financial position, results of operations, or cash flows.

 

Recent Accounting Standards Not Yet Adopted:

 

In November 2024, the FASB issued ASU 2024-03, – Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (“ASU 2024-03”). This ASU requires disclosures about specific types of expenses included in the expense captions presented on the face of the statement of operations as well as disclosures about selling expenses. The standard is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. The requirements will be applied prospectively with the option for retrospective application. Early adoption is permitted. The Company will evaluate the full extent of the adoption of ASU 2024-03 but believes it will not have a material impact on its consolidated financial statements and disclosures.

 

 
9

Table of Contents

 

In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements, which clarifies the applicability of Topic 270 and the form and content of interim financial statements. For public business entities, ASU 2025-11 is effective for interim reporting periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. The Company does not expect the adoption of ASU 2025-11 to have a material impact on its condensed consolidated financial statements and related disclosures.

 

The Company has also reviewed other recently issued accounting pronouncements and does not believe any such pronouncements will have a material impact on its condensed consolidated financial statements and related disclosures.

 

NOTE 3 – GOING CONCERN

 

The accompanying condensed consolidated financial statements have been prepared on a going concern basis which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the condensed consolidated financial statements, the Company has incurred recurring net losses since its inception and has raised limited capital. The Company had a net loss of $52,733 and $70,553 for the six months ended September 30, 2026, and September 30, 2025, respectively. The Company’s accumulated deficit was $35,716,936 and $35,554,968 as of September 30, 2026, and March 31, 2026, respectively. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or the amounts and classification of liabilities, that might be necessary should the Company be unable to continue as a going concern. The Company is taking certain steps to provide the necessary capital to continue its operations. These steps include but are not limited to: 1) focus on our new business model and 2) raising equity or debt financing.

 

NOTE 4 – CASH

 

The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. As of September 30, 2026, the Company’s cash consisted of non-restricted cash.

 

NOTE 5 – RELATED PARTY TRANSACTIONS

 

The Company had related party payables of $796,155 and $747,961 as of September 30, 2026, and March 31, 2026, respectively. These amounts consist of funds contributed by the management for the purpose of providing financing during periods of low or negative cashflow in order to cover essential costs of continuing operations, as well as funds payable to management as compensation. The amounts are unsecured, non-interest bearing and have no fixed terms of repayment. The related party payable consists of the following:

 

 

 

September 30, 2026

$

 

 

March 31, 2026

$

 

Accrued and unpaid compensation

 

 

248,000

 

 

 

248,000

 

Advances

 

 

548,155

 

 

 

499,961

 

Total related party payable

 

 

796,155

 

 

 

747,961

 

 

The changes in the related party payable during the six months ended September 30, 2026 were as follows:

 

 

 

$ 

 

Balance, March 31, 2026

 

 

747,961

 

Advances from Mr. Rodriguez, including $9,694 of Company costs paid directly by him

 

 

48,194

 

Compensation accrued, April 1 to June 30, 2026

 

 

12,000

 

Compensation forgiven and credited to additional paid-in capital

 

 

(12,000)

Balance, September 30, 2026

 

 

796,155

 

 

 
10

Table of Contents

 

 

No amounts were repaid to Mr. Rodriguez during the six months ended September 30, 2026.

 

The Company accrued compensation of $4,000 per month to Mr. Rodriguez under the terms of a four-year employment agreement entered into April 1, 2020, as extended on July 30, 2024 to March 31, 2026 and, effective April 1, 2026, for an additional two-year term to March 31, 2028 (the “Employment Contract”). By letter agreement dated as of July 31, 2026, the Company and Mr. Rodriguez terminated the Employment Contract effective June 30, 2026, and Mr. Rodriguez forgave $12,000 of compensation accrued and unpaid for the period April 1, 2026 to June 30, 2026. As Mr. Rodriguez is the Company’s controlling shareholder, the forgiveness was accounted for as a capital contribution and credited to additional paid-in capital. Mr. Rodriguez continues to serve as the Company’s sole officer and director without salary. The Company accrued compensation to Mr. Rodriguez of $12,000 and $24,000 for the six months ended September 30, 2026 and 2025, respectively. The Company also pays Mr. Rodriguez’s medical and dental insurance premiums while he serves as Chief Executive Officer, and paid his Medicare premiums through August 31, 2026. These premiums totaled $1,523 and $3,272 for the three and six months ended September 30, 2026, respectively, and are included in Selling, General and Administrative Expenses.

 

During each of the three months ended September 30, 2026, and 2025, the Company accrued $10,000 in preferred dividends from the Series A preferred shares to Mr. Kent Rodriguez, the sole shareholder of the Series A Preferred shares ($20,000 in each of the six-month periods). Upon conversion the number of shares of common stock to be exchanged for the Series A Preferred shares shall equal 51% of the then fully diluted issued and outstanding common stock at the time of conversion.

 

Until July 1, 2026, Mr. Rodriguez controlled Avalon 2015-1, LP, the holder of record of 368 shares (18.6%) of the Series B Preferred Stock, as its general partner. On July 1, 2026, Mr. Rodriguez assigned all of his interests in Avalon 2015-1, LP to an unrelated third party, who replaced him as its general partner. As a result, accrued and unpaid dividends of $107,884 on those shares were reclassified on July 1, 2026 from dividends payable, related party to dividends payable, and no Series B dividends have accrued for the benefit of Mr. Rodriguez since that date. The Company accrued Series B dividends for the benefit of Mr. Rodriguez of $8,299 and $16,598 for the six months ended September 30, 2026 and 2025, respectively.

 

NOTE 6 – ADVANCES PAYABLE

 

On September 23, 2026, the Company received an advance of $12,500 from an unrelated third party. The advance is unsecured, non-interest bearing and has no fixed terms of repayment.

 

NOTE 7 – PREFERRED STOCK

 

The Company is authorized to issue 1,000,000 shares of Preferred Stock. We have authorized 100 shares of Series A Preferred Stock and 2,000 shares of Series B Preferred Stock, respectively, both with a par value of $0.10. As of September 30, 2026 and March 31, 2026, there were 100 shares of Series A Preferred Stock and 1,983 shares of Series B Preferred Stock issued and outstanding.

 

Series A Preferred Stock holds designations of cash dividends at the rate of 8% of the amount per share of Series A Preferred Stock per annum in the form of “Preferred Dividends”, voting rights on an as-converted to Common Stock basis, liquidation preferences, and conversion rights in which each share of Series A Preferred Stock shall, upon conversion, represent 0.51% of the then “Fully-Diluted Shares Outstanding” of the Company. On January 12, 2018, our Board of Directors agreed to amend Designation of the Series A Convertible Preferred Stock be amended by changing the ratio for conversion, in Article IV, subparagraph (a), from 0.4% to 0.51% so that upon conversion the number of shares of common stock to be exchanged shall equal 51% of the then issued and outstanding common stock. In addition, on January 12, 2018, the Company and the Series A Holder agreed to forgive all accrued interest to date on Series A, and to pause any accruals until April 1, 2023. The Series A Convertible Preferred Stock carries liquidating preference, over all other classes of stock, equal to the amount paid for the stock plus any unpaid dividends. Currently the value of the liquidation preference is $500,000, the amount of debt that the related party converted into the preferred stock, plus accrued and unpaid dividends of $140,000. If this Preferred Stock were to be redeemed by the holder, it would result in an aggregate of the $500,000 liquidation preference, on a per share basis, this would equal $5,000 per share plus accrued and unpaid dividends. The Company and Series A Preferred Holder agreed to forgive all accrued interest and arrearages in preferred share dividends of Series A Preferred Stock through March 31, 2023. Dividends began to accrue on the Series A Preferred Stock as of April 1, 2023. During each of the six months ended September 30, 2026, and 2025, the holder of the Series A preferred shares, Mr. Kent Rodriguez, CEO, accrued $20,000 in preferred dividends from the Series A preferred shares. A total of $140,000 and $120,000 in accrued dividends with respect to the Series A preferred shares held by Mr. Rodriguez was outstanding at September 30, 2026, and March 31, 2026, respectively.

 

 
11

Table of Contents

 

 

Series B Preferred Stock holds designations of being ranked junior to the Series A Preferred Stock, cash dividends at the rate of 9% of the amount per share of Series B Preferred Stock per annum in the form of “Preferred Dividends”, a dividend received deduction for federal income tax purposes, liquidation preferences ranked junior to the Series A Preferred Stock, redemption of the Series B Preferred Stock by the Company at 105% of the Stated Value, plus accrued and unpaid Dividends, if prior to the two year anniversary of the Issuance Date, or at 100% of the Stated Value, plus accrued and unpaid Dividends, if on or after the two year anniversary of the Issuance Date, no voting rights, and right to notice of certain corporate actions. All accrued dividends on the Series B were settled through March 31, 2023, and none remained outstanding at March 31, 2023. Dividends began to accrue on the Series B Preferred Stock as of April 1, 2023. During each of the six months ended September 30, 2026 and 2025, the holders of the Series B preferred shares accrued $89,235 in preferred dividends from the Series B preferred shares. A total of $624,645 and $535,410 in Preferred B dividends was outstanding at September 30, 2026, and March 31, 2026, respectively. Dividends accrued for the benefit of Mr. Kent Rodriguez, CEO, through July 1, 2026 are described in Note 5.

 

A summary of accrued dividends payable with respect to the Series A and B Preferred shares on the Company’s balance sheets is set out below. Dividends accrued for the benefit of the Company’s CEO are included in Dividends payable, related party:

 

 

 

September 30, 2026

$

 

 

March 31, 2026

$

 

Dividends payable

 

 

624,645

 

 

 

435,825

 

Dividends payable, related party

 

 

140,000

 

 

 

219,585

 

 

NOTE 8 – COMMON STOCK

 

The Company is authorized to issue 200,000,000 shares of Common Stock, with a par value of $0.001.

 

The Company did not issue any shares of common stock during the six months ended September 30, 2026, or September 30, 2025, and had 59,643,062 shares of common stock issued and outstanding as of both September 30, 2026 and March 31, 2026.

 

NOTE 9 – COMMITMENTS AND CONTINGENCIES

 

As of September 30, 2026, the Company has a month-to-month verbal lease agreement with the landlord, in which the Company pays $1,200 on a monthly basis.

 

NOTE 10 – SEGMENT INFORMATION

 

The Company has one operating and reportable segment, which is the identification and evaluation of early-stage intellectual property and applied technologies for potential licensing, development or commercialization in North America. The Company has not generated any revenue. The Company’s chief operating decision maker (“CODM”) is its Chief Executive Officer, who is also its sole officer and director. The CODM assesses performance and decides how to allocate resources based on net loss, as reported in the condensed consolidated statements of operations, and uses net loss to monitor expenses and to determine the Company’s financing needs. The measure of segment assets is total assets, as reported on the condensed consolidated balance sheets, which were $18,762 and $4,432 as of September 30, 2026 and March 31, 2026, respectively. The significant segment expenses regularly provided to the CODM and the reconciliation of segment net loss to consolidated net loss were as follows:

 

 
12

Table of Contents

 

 

 

For the Three Months Ended

September 30,

 

 

For the Six Months Ended

September 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Revenue

 

$-

 

 

$-

 

 

$-

 

 

$-

 

Less significant segment expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling, General and Administrative Expenses

 

 

8,092

 

 

 

18,018

 

 

 

26,811

 

 

 

36,983

 

Rent

 

 

3,600

 

 

 

3,600

 

 

 

7,200

 

 

 

7,200

 

Legal and Professional Expenses

 

 

21,070

 

 

 

10,765

 

 

 

27,069

 

 

 

26,370

 

Less other segment items (1)

 

 

(1,200 )

 

 

-

 

 

 

(8,347 )

 

 

-

 

Segment and consolidated net loss

 

$(31,562 )

 

$(32,383 )

 

$(52,733 )

 

$(70,553 )

 

(1) Other segment items consist of other income. Segment net loss is the same as consolidated net loss, and there are no reconciling items.

 

NOTE 11 – SUBSEQUENT EVENTS

 

Management has evaluated subsequent events pursuant to the requirements of ASC Topic 855 and has determined that no material subsequent events exist through the date of this filing other than as set out below.

 

On October 20, 2026, our Board of Directors unanimously approved, and on October 20, 2026, Kent Rodriguez, our President, Chief Executive Officer and sole director, as the holder of all 100 outstanding shares of our Series A Convertible Preferred Stock and 4,367 shares of Common Stock, representing approximately 51% of the total voting power of our outstanding capital stock, approved by written consent in lieu of a meeting of stockholders, pursuant to Section 78.320 of the Nevada Revised Statutes (the “NRS”), the following corporate actions (collectively, the “Actions”):

 

 

(1)

Series A Anti-Call Amendment. An amendment to the Certificate of Designation of the Series A Preferred Stock to provide that the Company may not call, redeem or repurchase any shares of Series A Preferred Stock without the prior written consent of the holder(s) of such shares (the “Series A Amendment”); and

 

 

 

 

(2)

Series C Preferred Stock. The authorization, designation and approval of a new series of preferred stock designated “Series C Preferred Stock,” with an aggregate stated value of up to $15,000,000, on the principal terms summarized in the Company’s preliminary information statement on Schedule 14C filed with the SEC on October 20, 2026 (the “Series C Authorization”).

 

The Actions will not become effective until at least twenty (20) calendar days after the date on which the definitive Information Statement is first sent or given to our stockholders, in accordance with Rule 14c-2(b) under the Exchange Act. We currently anticipate that the definitive Information Statement will be filed with the SEC and first sent on or about December 9, 2026 to stockholders of record as of December 3, 2026, and that the Actions will become effective on or about December 30, 2026, upon the filing of the applicable Certificate(s) of Designation and amendment thereto with the Nevada Secretary of State, and the Company will not file those Nevada documents before December 30, 2026.

 

 
13

Table of Contents

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

This Quarterly Report on Form 10-Q contains predictions, estimates and other forward-looking statements relating to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “intends,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” or “continue” or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors including the risks set forth in the section entitled “Risk Factors” in our registration statement on Form 10-12G/A, as filed with the Securities and Exchange Commission (the “SEC”) on November 6, 2023, that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements.

 

Forward-looking statements represent our management’s beliefs and assumptions only as of the date of this Report. You should read this Report with the understanding that our actual future results may be materially different from what we expect.

 

All forward-looking statements speak only as of the date on which they are made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they are made, except as required by federal securities and any other applicable law.

 

The management’s discussion and analysis of our financial condition and results of operations are based upon our consolidated unaudited financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

 

The following discussion of our financial condition and results of operations should be read in conjunction with the notes to the consolidated unaudited financial statements appearing elsewhere in this Report and the Company’s audited financial statements for the fiscal year ended March 31, 2026, as filed with the SEC in its Annual Report on Form 10-K, along with the accompanying notes. As used in this Quarterly Report, the terms “we,” “us,” “our” and the “Company” means Groove Botanicals, Inc.

 

The Company relies primarily on its current sole officer and director, Kent Rodriguez to manage its day-to-day business and has outsourced professional services to third parties in an effort to maintain lower operational costs. Effective June 30, 2026, Mr. Rodriguez’s employment agreement was terminated and he continues to serve without salary, and the Company continues to pay his medical and dental insurance premiums.

 

Mr. Rodriguez, as the holder of the Company’s issued and outstanding shares of the Company’s Series A Preferred Stock, holds 51% of the voting rights of the Company. As a result, Mr. Rodriguez controls the outcome of all matters submitted to a vote of our stockholders, including the election of directors.

 

Plan of Operations

 

On September 14, 2023, we filed a registration statement on Form 10-12g which was deemed effective by the Securities and Exchange Commission (“SEC”) on November 13, 2023. The Company intends to change our name from Groove Botanicals, Inc., to Nordmark Technologies, Inc., to better describe our corporate focus. There can be no assurance that the name change will be completed.

 

We are an early-stage company. We intend to identify and evaluate early-stage intellectual property and applied technologies that may originate from, or be developed within, the research ecosystems of Norwegian universities, university hospitals, applied research institutions, and related technology-transfer or innovation organizations, and to assess whether selected technologies may be suitable for licensing, further development, or commercialization in North America through licensing, strategic relationships, commercial partnerships, customer arrangements, or other commercial structures, if available. We have selected an initial geographic focus on Norway as we believe a concentrated review of a defined research ecosystem may allow us to evaluate opportunities more efficiently, including energy and offshore technology, maritime and ocean industries, aquaculture, carbon capture, health sciences, medical technology, and other applied industrial and digital technologies.

 

 
14

Table of Contents

 

We do not currently have any products, technologies, or intellectual property rights. We have not entered into any licensing agreements or formal arrangements with any university, research institution, or technology transfer organization to date, and there can be no assurance that suitable technologies will be identified, licensed, developed, or successfully commercialized.

 

As the Company continues its business development and asset acquisitions, the Company anticipates our capital needs to be between $500,000 and $15,000,000 (varying based on growth strategies).

 

Results of Operations

 

Three Months Ended September 30, 2026, and September 30, 2025

 

Revenue

 

We have not generated any revenue since our inception and do not expect to generate any revenue from the sale of products in the near future.

 

Net Loss

 

We reported a net loss of $31,562 in the three months ended September 30, 2026 as compared to a loss of $32,383 in the three months ended September 30, 2025 and a net loss attributable to our common stockholders of $86,179 and $87,001, respectively, which includes accrued dividends on our Series A and B Preferred stock of $54,617 and $54,618 in the three months ended September 30, 2026 and 2025, respectively.

 

 

 

Three Months ended

 

 

 

September 30,

 

 

 

2026

 

 

2025

 

 

 

 

 

 

 

 

Net sales

 

$-

 

 

$-

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

Selling, General and Administrative Expenses

 

 

8,092

 

 

 

18,018

 

Rent

 

 

3,600

 

 

 

3,600

 

Legal and Professional Expenses

 

 

21,070

 

 

 

10,765

 

Total operating expenses

 

 

32,762

 

 

 

32,383

 

 

 

 

 

 

 

 

 

 

Income (loss) from operations

 

 

(32,762 )

 

 

(32,383 )

Other income

 

$1,200

 

 

$-

 

Total other income

 

$1,200

 

 

$-

 

 

 

 

 

 

 

 

 

 

Net income (loss)

 

$(31,562 )

 

$(32,383 )

 

 

 

 

 

 

 

 

 

Dividends on Preferred Stock

 

 

(54,617 )

 

 

(54,618 )

Net (loss) attributable to common stockholders

 

$(86,179 )

 

$(87,001 )

  

Operating Expenses

 

Total operating expenses for the three months ended September 30, 2026 were $32,762 compared to $32,383 for the three months ended September 30, 2025. Selling, General and Administrative Expenses decreased from $18,018 to $8,092, primarily because no compensation was accrued to our Chief Executive Officer following the termination of his employment agreement effective June 30, 2026, compared to $12,000 accrued in the prior-year period. Legal and Professional Expenses increased from $10,765 to $21,070, reflecting $15,000 of legal fees for the preparation of an information statement on Schedule 14C, partially offset by lower filing fees, which were $6,484 in the prior-year period when the Company re-filed certain prior SEC reports. Rent remained constant at $3,600. In addition, the Company recorded Other income of $1,200 during the three months ended September 30, 2026 from the write-off of a prior-period accounts payable balance for rent, following confirmation from the landlord that no amount was owed, with no comparable item in the prior-year period.

 

 
15

Table of Contents

 

Dividends on Preferred Stock

 

Dividends on Preferred Stock were $54,617 and $54,618 for the three months ended September 30, 2026 and 2025, respectively. These dividends on preferred stock are required subject to the designation of the preferred stock and contribute to the net loss attributable to our common stockholders.

 

Six Months Ended September 30, 2026, and September 30, 2025

 

Net Loss

 

We reported a net loss of $52,733 in the six months ended September 30, 2026 as compared to a loss of $70,553 in the six months ended September 30, 2025 and a net loss attributable to our common stockholders of $161,968 and $179,788, respectively, which includes accrued dividends on our Series A and B Preferred stock of $109,235 in each of the six months ended September 30, 2026 and 2025.

 

 

 

Six Months ended

 

 

 

September 30,

 

 

 

2026

 

 

2025

 

 

 

 

 

 

 

 

Net sales

 

$—

 

 

$—

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

Selling, General and Administrative Expenses

 

 

26,811

 

 

 

36,983

 

Rent

 

 

7,200

 

 

 

7,200

 

Legal and Professional Expenses

 

 

27,069

 

 

 

26,370

 

Total operating expenses

 

 

61,080

 

 

 

70,553

 

 

 

 

 

 

 

 

 

 

Income (loss) from operations

 

 

(61,080 )

 

 

(70,553 )

Other income

 

$8,347

 

 

$—

 

Total other income

 

$8,347

 

 

$—

 

 

 

 

 

 

 

 

 

 

Net income (loss)

 

$(52,733 )

 

$(70,553 )

 

 

 

 

 

 

 

 

 

Dividends on Preferred Stock

 

 

(109,235 )

 

 

(109,235 )

Net (loss) attributable to common stockholders

 

$(161,968 )

 

$(179,788 )

  

Operating Expenses

 

Total operating expenses for the six months ended September 30, 2026 were $61,080 compared to $70,553 for the six months ended September 30, 2025. Selling, General and Administrative Expenses decreased from $36,983 to $26,811, primarily because compensation accrued to our Chief Executive Officer was $12,000 compared to $24,000 in the prior-year period. Legal and Professional Expenses increased from $26,370 to $27,069, as $15,000 of legal fees for the Schedule 14C information statement were largely offset by lower audit fees following the Company’s change in independent registered public accounting firm in May 2026 and lower filing fees. Rent remained constant at $7,200. In addition, the Company recorded Other Income of $8,347 during the six months ended September 30, 2026, comprising a settlement of $7,147 received from the Company’s former independent registered public accounting firm, BF Borgers CPA PC, and $1,200 from the write-off of a prior-period accounts payable balance for rent, with no comparable items in the prior-year period.

 

 
16

Table of Contents

 

Dividends on Preferred Stock

 

Dividends on Preferred Stock were $109,235 for each of the six months ended September 30, 2026 and 2025.

 

Operating Activities

 

 

 

For the Six Months Ended

September 30,

 

 

 

2026

 

 

2025

 

Net Cash Used in Operating Activities

 

$(50,636 )

 

 

(44,854 )

Net Cash From Investing Activities

 

 

—

 

 

 

—

 

Net Cash From Financing Activities

 

 

51,000

 

 

 

44,304

 

Net Change in Cash

 

 

364

 

 

 

(550 )

Cash at End of Period

 

$1,866

 

 

$1,492

 

 

Net cash used by operating activities was $50,636 for the six months ended September 30, 2026, compared to $44,854 for the six months ended September 30, 2025.

 

Net cash used in operating activities for the six months ended September 30, 2026, was primarily the result of a net loss of $52,733, an increase in prepaid expenses of $13,770 and a decrease in accounts payable and accrued liabilities of $5,631, partially offset by non-cash accrued compensation of $12,000 and $9,694 of Company costs paid directly by our Chief Executive Officer.

 

Net cash used in operating activities for the six months ended September 30, 2025, was primarily the result of a net loss of $70,553, offset by non-cash items including accrued payroll of $24,000 and $10,820 of Company costs paid directly by our Chief Executive Officer, and changes in working capital related to an increase in prepaid expenses of $4,194 and a decrease in accounts payable and accrued liabilities of $4,927.

 

Investing Activities

 

There was no investing activity during each of the six months ended September 30, 2026 and 2025.

 

Financing Activities

 

Net cash provided by financing activities was $51,000 for the six months ended September 30, 2026, compared to $44,304 for the six months ended September 30, 2025. During the six months ended September 30, 2026, the Company received $38,500 in unsecured advances from our Chief Executive Officer, who also paid $9,694 of Company costs directly, with no funds repaid to the related party during the period, and a $12,500 advance from an unrelated third party. During the six months ended September 30, 2025, the Company received $46,500 in proceeds from a related party in the form of unsecured advances (in addition to $10,820 of Company costs the related party paid directly) and repaid $2,196 to a related party to reduce unsecured advances payable.

 

Liquidity and Capital Resources

 

We are in need of additional cash resources to maintain our operations. As of September 30, 2026, we had cash of $1,866 and prepaid expenses of $16,700. At September 30, 2026 we had a working capital deficit of $1,618,216, comprised of current assets of $18,762 and current liabilities of $1,636,978. Our current liabilities include $796,155 payable to our Chief Executive Officer for accrued compensation and unsecured advances, $764,645 of accrued and unpaid dividends on our Series A and Series B Preferred Stock and a $12,500 advance from a third party. Net cash used in operating activities was $50,636 for the six months ended September 30, 2026 and $44,854 for the six months ended September 30, 2025, funded principally by advances from our Chief Executive Officer.

 

We are in the early stage of development and have experienced net losses to date and have not generated revenue from operations, which raises substantial doubt about our ability to continue as a going concern. There are a number of conditions that we must satisfy before we will be able to acquire, license and acquire products and intellectual property, not the least of which is negotiating and financing any acquisitions. We are in the process of identifying and establishing strategic partners and technologies in order to establish a market and generate commercial orders by customers and licensing which will include effective marketing and sales capabilities for any products. We do not currently have sufficient resources to accomplish any of these conditions necessary for us to generate revenue and expect to incur increasing operating expenses. We will require substantial additional funds for operations and to fund our business objectives. There can be no assurance that financing, whether debt or equity, will always be available to us in the amount required at any particular time or for any particular period or, if available, that it can be obtained on terms favorable to us. If additional funds are raised by the issuance of equity securities, such as through the issuance and exercise of warrants, then existing stockholders will experience dilution of their ownership interest. If additional funds are raised by the issuance of debt or other equity instruments, we may be subject to certain limitations in our operations, and issuance of such securities may have rights senior to those of the then existing stockholders. We currently have no agreements, arrangements or understandings with any person or entity to obtain funds through bank loans, lines of credit or any other sources.

 

 
17

Table of Contents

 

Going Concern

 

The accompanying condensed consolidated financial statements have been prepared on a going concern basis which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the condensed consolidated financial statements, the Company has incurred recurring net losses since its inception and has raised limited capital. The Company had a net loss of $52,733 and $70,553 for the six-month periods ended September 30, 2026, and 2025, respectively. The Company’s accumulated deficit was $35,716,936 and $35,554,968 as of September 30, 2026, and March 31, 2026, respectively. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or the amounts and classification of liabilities, that might be necessary should the Company be unable to continue as a going concern. The Company is taking certain steps to provide the necessary capital to continue its operations. These steps include but are not limited to: 1) focus on our new business model and 2) raising equity or debt financing.

 

Off-Balance Sheet Arrangements

 

We have no off-balance sheet arrangements.

 

Critical Accounting Estimates

 

The financial statements are prepared in accordance with accounting principles generally accepted in the U.S. (“GAAP”). The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, costs and expenses and related disclosures. We base our estimates on historical experience, as appropriate, and on various other assumptions that we believe are reasonable under the circumstances. Changes in the accounting estimates are reasonably likely to occur from period to period. Accordingly, actual results could differ significantly from the estimates made by our management. We evaluate our estimates and assumptions on an ongoing basis. To the extent that there are material differences between these estimates and actual results, our future financial statement presentation, financial condition, results of operations and cash flows will be affected. Our significant accounting policies are more fully discussed in Note 2 to our unaudited condensed financial statements contained herein.

 

Use of Estimates

 

The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Specifically, such estimates were made by the Company for the accrual of Series A and Series B preferred dividends, accrued related-party compensation and advances, and the assessment of the Company’s ability to continue as a going concern. Actual results could differ from those estimates.

 

Recent Accounting Pronouncements

 

In November 2023, the FASB issued Accounting Standards Update (“ASU”) 2023-07 – Improvements to Reportable Segment Disclosures, which enhances the disclosures required for reportable segments in annual and interim financial statements, including additional, more detailed information about a reportable segment’s expenses. The standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company adopted ASU 2023-07 for the year ended March 31, 2025, retrospectively to all periods presented in the financial statements. The adoption of this ASU had no impact on reportable segments identified and had no effect on the Company’s financial position, results of operations, or cash flows. In December 2023, the FASB issued ASU 2023-09 – Improvements to Income Tax Disclosures, which enhances the transparency and decision usefulness of income tax disclosures. The Company adopted ASU 2023-09 for the year beginning April 1, 2025. The adoption of this ASU had no impact on the Company’s financial position, results of operations, or cash flows.

 

 
18

Table of Contents

 

Recent Accounting Standards Not Yet Adopted:

 

In November 2024, the FASB issued ASU 2024-03, – Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (“ASU 2024-03”). This ASU requires disclosures about specific types of expenses included in the expense captions presented on the face of the statement of operations as well as disclosures about selling expenses. The standard is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. The requirements will be applied prospectively with the option for retrospective application. Early adoption is permitted. The Company will evaluate the full extent of the adoption of ASU 2024-03, but believes it will not have a material impact on its consolidated financial statements and disclosures. The Company has also reviewed other recently issued accounting pronouncements and does not believe any such pronouncements will have a material impact on its condensed consolidated financial statements and related disclosures.

 

In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements, which clarifies the applicability of Topic 270 and the form and content of interim financial statements. For public business entities, ASU 2025-11 is effective for interim reporting periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. The Company does not expect the adoption of ASU 2025-11 to have a material impact on its condensed consolidated financial statements and related disclosures.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

We are a smaller reporting company and are not required to provide this information.

 

ITEM 4. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, as of September 30, 2026, we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) and Rule 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended. Based on this evaluation, our principal executive officer and principal financial officer have concluded that, based on the material weaknesses discussed below, our disclosure controls and procedures were not effective as of such date to ensure that information required to be disclosed by us in reports filed or submitted under the Securities Exchange Act were recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Act Commission’s rules and forms and that our disclosure controls are not effectively designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act is accumulated and communicated to management, including our principal executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

 

 
19

Table of Contents

 

Our internal controls and procedures are not effective for the following reasons: (i) there is an inadequate segregation of duties consistent with control objectives as management is comprised of only one person, who is the Company’s principal executive officer and principal financial officer and, (ii) the Company does not have a formal audit committee with a financial expert, and thus the Company lacks the board oversight role within the financial reporting process.

 

In order to mitigate the foregoing material weakness, we have engaged an outside accounting consultant with significant experience in the preparation of financial statements in conformity with GAAP to assist us in the preparation of our financial statements to ensure that these financial statements are prepared in conformity with GAAP. We will continue to monitor the effectiveness of this action and make any changes that our management deems appropriate.

 

We would need to hire additional staff to provide greater segregation of duties. Currently, it is not feasible to hire additional staff to obtain optimal segregation of duties. Management will continue to reassess this matter to determine whether improvement in segregation of duty is feasible. In addition, we would need to expand our board to include independent members.

 

Going forward, we intend to evaluate our processes and procedures and, where practicable and resources permit, implement changes in order to have more effective controls over financial reporting.

 

Changes in Internal Control over Financial Reporting

 

During the period covered by this report, there were no changes in our internal controls over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

 
20

Table of Contents

 

PART II – OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

There are no pending legal proceedings to which the Company is a party or in which any director, officer or affiliate of the Company, any owner of record or beneficially of more than 5% of any class of voting securities of the Company, or security holder is a party adverse to the Company or has a material interest adverse to the Company. The Company’s property is not the subject of any pending legal proceedings.

 

ITEM 1A. RISK FACTORS

 

The Company is a smaller reporting company and is not required to provide this information.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

There were no shares issued during the six-month period ended September 30, 2026 or the six-month period ended September 30, 2025. Total issued and outstanding shares of common stock are 59,643,062 at September 30, 2026 and 2025. The Company did not purchase any of its equity securities during the six months ended September 30, 2026.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not Applicable

 

ITEM 5. OTHER INFORMATION

 

Termination of Employment Contract. By letter agreement dated as of July 31, 2026, the Company and Mr. Kent Rodriguez, its Chief Executive Officer and sole director, terminated the employment contract between them dated April 1, 2020, as extended to March 31, 2028, effective June 30, 2026. Under that contract Mr. Rodriguez was entitled to compensation of $4,000 per month. In connection with the termination, Mr. Rodriguez forgave $12,000 of compensation accrued and unpaid for the period April 1, 2026 to June 30, 2026. Mr. Rodriguez continues to serve as the Company’s President, Chief Executive Officer, Chief Financial Officer and sole director without salary, and the Company continues to pay his medical and dental insurance premiums while he serves as Chief Executive Officer. The Company did not incur any termination penalties.

 

Rule 10b5-1 Trading Arrangements. During the three months ended September 30, 2026, no director or officer of the Company adopted or terminated any contract, instruction or written plan for the purchase or sale of Company securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Securities Exchange Act of 1934, or any non-Rule 10b5-1 trading arrangement as defined in Item 408(c) of Regulation S-K.

 

 
21

Table of Contents

 

ITEM 6. EXHIBITS

 

Exhibit Number

 

Exhibit

 

 

 

10.1

 

Letter agreement dated as of July 31, 2026 between Groove Botanicals, Inc. and Kent Rodriguez terminating the Employment Contract

 

 

 

31

 

Certification of the Principal Executive Officer and Principal Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

 

 

32

 

Certification of the Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial Officer) pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350)

 

 

 

101

 

Inline XBRL (Extensible Business Reporting Language). The following materials from this Quarterly Report on Form 10-Q for the period ended September 30, 2026, are formatted in Inline XBRL: (i) condensed consolidated balance sheets of Groove Botanicals, Inc., (ii) condensed consolidated statements of operations of Groove Botanicals, Inc., (iii) condensed consolidated statements of stockholders’ equity of Groove Botanicals, Inc., (iv) condensed consolidated statements of cash flows of Groove Botanicals, Inc. and (v) notes to condensed consolidated financial statements of Groove Botanicals, Inc. The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.

 

 

 

104

 

Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL.

 

 
22

Table of Contents

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

GROOVE BOTANICALS, INC.

 

 

 

 

Date: November 12, 2026

By:

/s/ Kent Rodriguez

 

 

 

Kent Rodriguez

 

 

 

Chief Executive Officer and Chief Financial Officer

(Principal Executive Officer and Principal Financial

and Accounting Officer) 

 

 
23